The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A

Cunningham, William E.; Andersen, Ronald; Dietrich, Shelby L.; Curtis, Randall; Parish, Kathy L.; Miller, Robert; Sanders, N. L.; Kominski, Gerald F.

doi:10.1046/j.1365-2516.2003.00752.x

Cited by 29 publications

(35 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Globe et al 17,18 conducted a medical record review at three California hemophilia treatment centers. These previous studies also found that patients with inhibitors had higher costs than patients with moderate hemophilia.…”

Section: Discussionmentioning

confidence: 99%

Costs and utilization of hemophilia A and B patients with and without inhibitors

Armstrong¹,

Malone²,

Krishnan³

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

The results suggest that, while the frequency of inhibitors within the hemophilia cohort was low, there was a higher frequency of hospitalizations, and the associated median aggregate costs per year were 3-fold higher than those patients without inhibitors. In contrast, hemophilia B patients experience less severe disease and account for lower aggregate yearly costs compared to either patients with hemophilia A or patients with inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

Costs and utilization of hemophilia A and B patients with and without inhibitors

Armstrong¹,

Malone²,

Krishnan³

et al. 2014

Journal of Medical Economics

View full text Add to dashboard Cite

show abstract

“…foundnostatisticallysignificant associationbetween occurrenceso fi npatient hospitalizationa nd HIVs tatusa fter adjustingfor severity of hemophilia. 15,16 With currenttreatmentof HIVe ffectivelymakingi tac hronic condition, it is possible that Medical Costs andResource Utilization for HemophiliaPatientsWith andWithoutHI VorHCV Infection severity and agea re theb iggest predictors of hospitalizationi n coinfected hemophiliap atientsand attenuatethe impact of viral coinfection.…”

Section: ■■ Discussionmentioning

confidence: 99%

“…WhileG lobe at al.d id not findas tatistically significantassociation betweenHIV positivity andt he number of hospitalizationso rt he number of inpatient hospital days,M inerse ta l. foundt hatH IV-positiveh emophilia patients were more likelyt ohave outpatienth ospitalvisitsthan were hemophiliap atientsw ho were HIVn egative. 15,16 Moreover, in hemophiliap atientsi nfected with HIV, ad ecreasei nC D4+ counts has been associated with an increase in clottingf actor utilization,withend-stage AIDS hemophiliapatientsconsuming upward of 50%m orec lottingf actort hanw hent heya re asymptomatic. 17 Hemophilia is ac hronic ande xpensive condition,w ith antihemophilicm edications accountingf or 45%-93%o ft otal health care costs, dependingonseverity andtreatment regimen.…”

Section: What Is Alreadyknownaboutthissubjectmentioning

confidence: 99%

Medical Costs and Resource Utilization for Hemophilia Patients With and Without HIV or HCV Infection

Tencer

Frıedman²,

Li-McLeod³

et al. 2007

JMCP

View full text Add to dashboard Cite

“…The total cost of care of patients including products, routine diagnostics and treatment services are paid by the insurance system and the Ministry of Health in Iran. In one study in the Fars province of Iran, the factor cost was 99% of the total cost of care [46], which is high in comparison with the USA, UK and Italy (72, 29 and 32% respectively) [47, 48]. …”

Section: Treatment and Diagnostic Facilitiesmentioning

confidence: 99%

Haemophilia in the developing countries: the Iranian experience

Eshghi¹,

Mahdavi‐Mazdeh²,

Karimi³

et al. 2010

aoms

View full text Add to dashboard Cite

IntroductionManagement of haemophilia and inherited bleeding disorders is a major challenge especially in developing countries, because of a shortage or absence of products, the cost and the infrastructural health problems. Development of local expertise which results in an improved outlook and reduction in mortality and morbidity in these countries can be helpful for advocators in other developing countries. However, very little information on demography and organizational models for haemophilia care in developing countries are available in the literature. Our aim is a comprehensive report of haemophilia status and its management in Iran.Material and methodsThe Management Center of Transplantation and Special Diseases (MCTSD) of the Ministry of Health of Iran decided to carry out a complete review and compilation of all of the published or available data about patients with haemophilia (PWH) in Iran: their health status, their management planning, organizations, treatment products, facilities and care problems during 2007.Results6496 patients with congenital bleeding disorders were registered. Most of them had haemophilia A and B and von Willebrand disease (vWD). However, rare bleeding disorders are seen more than expected. Inhibitor development is 14–28%. There are different data about virological status of PWH. Factor products and facilities are fairly available with more than 1.5 units per capita of inhabitant factor consumption.ConclusionsA national formulary based on facilities of the country should be considered and followed by collaboration among the Ministry Of Health, universities and non-governmental organizations.

show abstract

The Hemophilia Utilization Group Study (HUGS): determinants of costs of care in persons with haemophilia A

Cited by 29 publications

References 16 publications

Costs and utilization of hemophilia A and B patients with and without inhibitors

Costs and utilization of hemophilia A and B patients with and without inhibitors

Medical Costs and Resource Utilization for Hemophilia Patients With and Without HIV or HCV Infection

Haemophilia in the developing countries: the Iranian experience

Contact Info

Product

Resources

About